2014
DOI: 10.1016/j.canlet.2014.08.014
|View full text |Cite
|
Sign up to set email alerts
|

Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts stimulates the progression of gastric cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
74
1

Year Published

2015
2015
2020
2020

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 72 publications
(79 citation statements)
references
References 27 publications
4
74
1
Order By: Relevance
“…We can only speculate that the properties of CAFs, which can promote cancer progression, depend on a constant cross talk with cancer cells, and thus CAFs may not be formed in the early phase of the disease. In fact, several specific biomarkers determining the characteristics of CAFs, such as Twist-related protein 1, tumor endothelial marker 1, and lysyl oxidase like 2, are frequently overexpressed in the fibroblasts of GCs with higher T categories [22,30,31], supporting the notion that ''fully activated CAFs'' may be completed in an advanced stage of disease, with an increased number of CAFs, as shown by our data.…”
Section: Discussionsupporting
confidence: 67%
“…We can only speculate that the properties of CAFs, which can promote cancer progression, depend on a constant cross talk with cancer cells, and thus CAFs may not be formed in the early phase of the disease. In fact, several specific biomarkers determining the characteristics of CAFs, such as Twist-related protein 1, tumor endothelial marker 1, and lysyl oxidase like 2, are frequently overexpressed in the fibroblasts of GCs with higher T categories [22,30,31], supporting the notion that ''fully activated CAFs'' may be completed in an advanced stage of disease, with an increased number of CAFs, as shown by our data.…”
Section: Discussionsupporting
confidence: 67%
“…The methods used for the immunohistochemical determination are described in the kit manufacturer's instructions, as previously reported [14]. LOX expression was evaluated by the intensity of staining and the percentage of stained cancer cells at the invading tumor front: intensity was given a score ranging from 0 to 2 (0 = no intensity, 1 = weak to moderate intensity, 2 = intense intensity), and the percentage of immunopositive cells was given a score ranging from 0 to 4 (0 = 0 %, 1 = 1-30 %, 2 = 31-60 %, 3 = 61-80 %, 4 = 81-100 %).…”
Section: Immunohistochemical Determination Of Loxmentioning
confidence: 99%
“…LOX and its family members, LOX-like 1-4, oxidize lysine residues in collagens and elastin [10], which results in covalent cross-linking and stabilization of these extracellular matrix structural components, conferring on collagen and elastic fibers much of their tensile strength [11]. LOX families are involved in a variety of pathological processes related to connective tissue [12,13], including cancer progression and metastasis [11,14]. Involvement of the LOX family is widely accepted as a poor prognostic factor for patients with cancer [15][16][17][18][19][20].…”
Section: Introductionmentioning
confidence: 99%
“…201,245 Alternatively, LOXL2 may be secreted by local CAFs to influence ECM composition, and this has been shown in gastric cancer cell lines to be associated with increased aggressiveness. 251 In addition, increased LOXL2 expression in CAFs is associated with reduced OS and increased recurrence in colon cancer patients. 247 The…”
Section: Discussionmentioning
confidence: 99%
“…250 LOXL2 may be secreted by stromal cancer-associated fibroblasts or tumour cells. 247,251 LOXL2 secreted by tumour cells has also been shown to activate stromal fibroblasts and cause local desmoplasia (fibrosis), possibly via FAK (focal adhesion kinase) signalling. 199 Increased expression of LOXL2 in stromal fibroblasts has also been shown to be associated with aggressiveness in gastric cancer.…”
Section: Discussionmentioning
confidence: 99%